(Q35621634)

9 August 2017

1 reference

title

Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics (English)

1 reference

9 August 2017

1 reference

1 reference

Jean-Michel Pawlotsky

series ordinal

1

object named as

Jean-Michel Pawlotsky

0 references

author name string

Jean-Michel Pawlotsky

series ordinal

1

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S31-5

1 reference

Kinetics of acute hepatitis B virus infection in humans.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Molecular diagnosis of viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Detection and quantitation of hepatitis B virus DNA: comparison of two commercial hybridization assays with polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Quantitative detection of hepatitis B virus DNA in serum using chemiluminescence: comparison with radioactive solution hybridization assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

What technique should be used for routine detection and quantification of HBV DNA in clinical samples?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Second-generation Hybrid capture test and Amplicor monitor test generate highly correlated hepatitis B virus DNA levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Serum HBV-DNA levels in inactive hepatitis B virus carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Clinical utility in quantifying serum HBV DNA levels using PCR assays

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Clinical implications of lamivudine resistance by HBV

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900136-3

7 January 2021

10.1016/S0168-8278(03)00136-3

Identifiers

DOI

1 reference

9 August 2017

1 reference